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We thank Ahmed and colleagues for their kind and inter-
esting comments. The authors pointed out the classical di-
vergence between observational and experimental results.
Observational studies are prone to reverse causation and
confounding [1]. Associations between vitamin D status
and cardiovascular health outcomes in observational stud-
ies could merely indicate that vitamin D is a “simple” in-
dicator of health status; compared with healthier subjects,
sicker subjects could have lower vitamin D levels or status.
The diversity of biological systems with which vitamin D
deficiency has been associated (cardiovascular, diabetes,
depression, neurodegenerative diseases, cancers, etc.)
[2–4] could further suggest that vitamin D is a marker of
health status rather than a predictor of health outcomes.
Yet, both the wide distribution of vitamin D receptors in
the human organism [5] and the influence of vitamin D on
more than 3% of the human genome [6] could explain the
broad influence of vitamin D on health.
Randomised clinical trials testing the efficacy of vitamin
D supplementation in reducing cardiovascular events are
ongoing. The Vitamin D and Omega 3 Trial (VITAL, US
clinical trial registry number: NCT01169259) is investig-
ating, in 20,000 USA adults, whether taking daily dietary
supplements of vitamin D3 (2000 IU) or omega-3 fatty
acids for 5 years reduces the risk of developing cancer
and cardiovascular disease. The Vitamin D Assessment
Study (ViDa, ANZCTR clinical trial registry number:
ANZCTR12611000402943) is investigating, in 5,100
adults in New Zealand, whether taking vitamin D3 200,000
IU at baseline and 100,000 IU monthly for 4 years reduces
the risk of cardiovascular disease. Both trials are still re-
cruiting participants and first results will not be available
before year 2016. Meanwhile, we agree with Ahmed and
colleagues that the previously reported associations of vit-
amin D with cardiovascular disease should not be inter-
preted as causal.
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